776-09-0

Basic information

• Product Name: 2,3,5,6-tetrafluorobenzenesulfonyl chloride
• Synonyms: 2,3,5,6-tetrafluorobenzenesulfonyl chloride
• CAS NO: 776-09-0
• Molecular Weight: 248.585
• Mol File: 776-09-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,3,5,6-tetrafluorobenzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,5,6-tetrafluorobenzenesulfonyl chloride(776-09-0)
• EPA Substance Registry System: 2,3,5,6-tetrafluorobenzenesulfonyl chloride(776-09-0)

Safety Data

• Hazardous Substances Data: 776-09-0(Hazardous Substances Data)

Usage

General Description

2,3,5,6-tetrafluorobenzenesulfonyl chloride is a chemical compound with the molecular formula C6H2F4O2SCl. It is a sulfonyl chloride derivative of benzene, with four fluorine atoms attached to the benzene ring. This chemical is used as a versatile reagent in organic synthesis, particularly in the introduction of the sulfonyl group into various organic molecules. It is also used in the production of pharmaceuticals, agrochemicals, and materials science. Due to its strong reactivity, 2,3,5,6-tetrafluorobenzenesulfonyl chloride is handled and synthesized with caution in a controlled laboratory environment.

Upstream product

• 1835-61-6 1-chloro-2,3,5,6-tetrafluorobenzene 
• 1376608-47-7 benzyl (2,3,5,6-tetrafluorophenyl)sulfane 
• 40707-55-9 2,3,5,6-tetrafluorobenzenesulfonic acid 
• 327-54-8 1,2,4,5-Tetrafluorobenzene 

Downstream Products

• 52331-34-7 2,3,5,6-tetrafluorobenzenesulphonyl fluoride 
• 651-81-0 2,3,5,6-tetrafluorobenzenesulfonamide 

Relevant articles and documents

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HDAC) inhibitors are increasingly used for targeted therapy. Through a structure-activity relationship (SAR) study, we developed an HDAC6 inhibitor KT-531, which exhibited higher potency in T-PLL compared to other hematological cancers. KT-531 displayed strong HDAC6 inhibitory potency and selectivity, on-target biological activity, and a safe therapeutic window in nontransformed cell lines. In primary T-PLL patient cells, whereHDAC6was found to be overexpressed, KT-531 exhibited strong biological responses, and safety in healthy donor samples. Notably, combination studies in T-PLL patient samples demonstrated KT-531 synergizes with approved cancer drugs, bendamustine, idasanutlin, and venetoclax. Our work suggests HDAC inhibition in T-PLL could afford sufficient therapeutic windows to achieve durable remission either as stand-alone or in combination with targeted drugs.

Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered

Polyfluorinated CAIs show very good inhibitory properties against different carbonic anhydrase (CA) isozymes, such as CA I, II, and IV, but such compounds have not been tested for their interaction with the transmembrane, tumor-associated isozyme CA IX. Thus, a series of such compounds has been obtained by attaching 2,3,5,6-tetrafluorobenzoyl- and 2,3,5,6- tetrafluorophenylsulfonyl- moieties to aromatic/heterocyclic sulfonamides possessing derivatizable amino moieties. Some of these compounds showed excellent CA IX inhibitory properties and also selectivity ratios favorable to CA IX over CA II, the other physiologically relevant isozyme with high affinity for sulfonamide inhibitors. The first subnanomolar and rather selective CA IX inhibitor has been discovered, as the 2,3,5,6-tetrafluorobenzoyl derivative of metanilamide showed an inhibition constant of 0.8nM against hCA IX, and a selectivity ratio of 26.25 against CA IX over CA II. Several other low nanomolar CA IX inhibitors were detected among the new derivatives reported here. The reported derivatives constitute valuable candidates for the development of novel antitumor therapies based on the selective inhibition of tumor-associated CA isozymes.